DEC orders changes at Great Lakes Cheese after Ischua Creek fish kill
Breaking News
DEC orders changes at Great Lakes Cheese after Ischua Creek fish kill
By BOB CLARK bclark@oleantimesherald.com 
August 29, 2025
FRANKLINVILLE — State environmental officers said immediate changes are needed after a fish kill in Ischua Creek was triggered by pollution from the G...
Home Online Features Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
Hand-out
Press Releases
Syndax Pharmaceuticals, Inc.  
November 15, 2024

Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

– Approval based on positive data from the AUGMENT-101 clinical trial, in which Revuforj delivered robust and durable rates of remission in R/R acute leukemia patients with a KMT2A translocation

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social